Literature DB >> 27421752

Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment.

Aline Talhouk1, Lien N Hoang2, Melissa K McConechy3, Quentin Nakonechny4, Joyce Leo4, Angela Cheng5, Samuel Leung5, Winnie Yang1, Amy Lum1, Martin Köbel6, Cheng-Han Lee7, Robert A Soslow8, David G Huntsman1, C Blake Gilks4, Jessica N McAlpine9.   

Abstract

OBJECTIVE: Categorization and risk stratification of endometrial carcinomas is inadequate; histomorphologic assessment shows considerable interobserver variability, and risk of metastases and recurrence can only be derived after surgical staging. We have developed a Proactive Molecular Risk classification tool for Endometrial cancers (ProMisE) that identifies four distinct prognostic subgroups. Our objective was to assess whether molecular classification could be performed on diagnostic endometrial specimens obtained prior to surgical staging and its concordance with molecular classification performed on the subsequent hysterectomy specimen.
METHODS: Sequencing of tumors for exonuclease domain mutations (EDMs) in POLE and immunohistochemistry for mismatch repair (MMR) proteins and p53 were applied to both pre- and post-staging archival specimens from 60 individuals to identify four molecular subgroups: MMR-D, POLE EDM, p53 wild type, p53 abn (abnormal). Three gynecologic subspecialty pathologists assigned histotype and grade to a subset of samples. Concordance of molecular and clinicopathologic subgroup assignments were determined, comparing biopsy/curetting to hysterectomy specimens.
RESULTS: Complete molecular and pathologic categorization was achieved in 57 cases. Concordance metrics for pre- vs. post-staging endometrial samples categorized by ProMisE were highly favorable; average per ProMisE class sensitivity(0.9), specificity(0.96), PPV(0.9), NPV(0.96) and kappa statistic 0.86(95%CI, 0.72-0.93), indicating excellent agreement. We observed the highest level of concordance for 'p53 abn' tumors, the group associated with the worst prognosis. In contrast, grade and histotype assignment from original pathology reports pre- vs. post-staging showed only moderate levels of agreement (kappa=0.55 and 0.44 respectively); even with subspecialty pathology review only moderate levels of agreement were observed.
CONCLUSION: Molecular classification can be achieved on diagnostic endometrial samples and accurately predicts the molecular features in the final hysterectomy specimens, demonstrating concordance superior to grade and histotype. This biologically relevant information, available at initial diagnosis, has the potential to inform management (surgery, adjuvant therapy) from the earliest time point in cancer care.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27421752      PMCID: PMC5521211          DOI: 10.1016/j.ygyno.2016.07.090

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  38 in total

1.  Immunophenotypic features of dedifferentiated endometrial carcinoma - insights from BRG1/INI1-deficient tumours.

Authors:  Lien N Hoang; Yow-Shan Lee; Anthony N Karnezis; Basile Tessier-Cloutier; Noorah Almandani; Mackenzie Coatham; C Blake Gilks; Robert A Soslow; Colin J R Stewart; Martin Köbel; Cheng-Han Lee
Journal:  Histopathology       Date:  2016-07-05       Impact factor: 5.087

2.  Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas.

Authors:  M K McConechy; A Talhouk; H H Li-Chang; S Leung; D G Huntsman; C B Gilks; J N McAlpine
Journal:  Gynecol Oncol       Date:  2015-01-28       Impact factor: 5.482

3.  Histotype-genotype correlation in 36 high-grade endometrial carcinomas.

Authors:  Lien N Hoang; Melissa K McConechy; Martin Köbel; Guangming Han; Marjan Rouzbahman; Ben Davidson; Julie Irving; Rola H Ali; Sam Leung; Jessica N McAlpine; Esther Oliva; Marisa R Nucci; Robert A Soslow; David G Huntsman; C Blake Gilks; Cheng-Han Lee
Journal:  Am J Surg Pathol       Date:  2013-09       Impact factor: 6.394

4.  Discrepancy of pre- and postoperative grades of patients with endometrial carcinoma.

Authors:  A Karateke; N Tug; C Cam; S Selcuk; M R Asoglu; S Cakir
Journal:  Eur J Gynaecol Oncol       Date:  2011       Impact factor: 0.196

5.  Prognosis and reproducibility of new and existing binary grading systems for endometrial carcinoma compared to FIGO grading in hysterectomy specimens.

Authors:  Hui Guan; Assaad Semaan; Sudeshna Bandyopadhyay; Haitham Arabi; Jining Feng; Lamia Fathallah; Vaishali Pansare; Aamer Qazi; Fadi Abdul-Karim; Robert T Morris; Adnan R Munkarah; Rouba Ali-Fehmi
Journal:  Int J Gynecol Cancer       Date:  2011-05       Impact factor: 3.437

Review 6.  Predictive Modeling: A New Paradigm for Managing Endometrial Cancer.

Authors:  Sofiane Bendifallah; Emile Daraï; Marcos Ballester
Journal:  Ann Surg Oncol       Date:  2015-11-17       Impact factor: 5.344

Review 7.  Classification of endometrial carcinoma: more than two types.

Authors:  Rajmohan Murali; Robert A Soslow; Britta Weigelt
Journal:  Lancet Oncol       Date:  2014-06       Impact factor: 41.316

8.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

9.  Prediction of cancer incidence and mortality in Korea, 2014.

Authors:  Kyu-Won Jung; Young-Joo Won; Hyun-Joo Kong; Chang-Mo Oh; Duk Hyoung Lee; Jin Soo Lee
Journal:  Cancer Res Treat       Date:  2014-04-22       Impact factor: 4.679

10.  Assessment of endometrial sampling as a predictor of final surgical pathology in endometrial cancer.

Authors:  L Helpman; R Kupets; A Covens; R S Saad; M A Khalifa; N Ismiil; Z Ghorab; V Dubé; S Nofech-Mozes
Journal:  Br J Cancer       Date:  2013-12-24       Impact factor: 7.640

View more
  35 in total

Review 1.  The roles of pathology in targeted therapy of women with gynecologic cancers.

Authors:  Rajmohan Murali; Rachel N Grisham; Robert A Soslow
Journal:  Gynecol Oncol       Date:  2017-11-23       Impact factor: 5.482

Review 2.  The evolution of endometrial carcinoma classification through application of immunohistochemistry and molecular diagnostics: past, present and future.

Authors:  Emily A Goebel; August Vidal; Xavier Matias-Guiu; C Blake Gilks
Journal:  Virchows Arch       Date:  2017-12-12       Impact factor: 4.064

3.  Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups.

Authors:  Tjalling Bosse; Remi A Nout; Jessica N McAlpine; Melissa K McConechy; Heidi Britton; Yaser R Hussein; Carlene Gonzalez; Raji Ganesan; Jane C Steele; Beth T Harrison; Esther Oliva; August Vidal; Xavier Matias-Guiu; Nadeem R Abu-Rustum; Douglas A Levine; C Blake Gilks; Robert A Soslow
Journal:  Am J Surg Pathol       Date:  2018-05       Impact factor: 6.394

4.  Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers.

Authors:  Marisa R Moroney; Kurtis D Davies; Adam C Wilberger; Jeanelle Sheeder; Miriam D Post; Amber A Berning; Christine Fisher; Carolyn Lefkowits; Saketh R Guntupalli; Kian Behbakht; Bradley R Corr
Journal:  Gynecol Oncol       Date:  2019-03-22       Impact factor: 5.482

Review 5.  Controversies in the Management of Early-stage Serous Endometrial Cancer.

Authors:  Alyssa Larish; Andrea Mariani; Carrie Langstraat
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

6.  Prognostic impact of histological review of high-grade endometrial carcinomas in a large Danish cohort.

Authors:  Marie Boennelycke; Elke E M Peters; Alicia Léon-Castillo; Vincent T H B M Smit; Tjalling Bosse; Ib Jarle Christensen; Gitte Ørtoft; Claus Høgdall; Estrid Høgdall
Journal:  Virchows Arch       Date:  2021-06-11       Impact factor: 4.064

7.  DNA Mismatch Repair-deficient Endometrial Carcinosarcomas Portend Distinct Clinical, Morphologic, and Molecular Features Compared With Traditional Carcinosarcomas.

Authors:  Sheila E Segura; Silvana Pedra Nobre; Yaser R Hussein; Nadeem R Abu-Rustum; Britta Weigelt; Robert A Soslow; Deborah F DeLair
Journal:  Am J Surg Pathol       Date:  2020-11       Impact factor: 6.394

8.  Clinicopathologic and Genomic Analysis of TP53-Mutated Endometrial Carcinomas.

Authors:  Lora H Ellenson; Britta Weigelt; Robert A Soslow; Amir Momeni-Boroujeni; Wissam Dahoud; Chad M Vanderbilt; Sarah Chiang; Rajmohan Murali; Eric V Rios-Doria; Kaled M Alektiar; Carol Aghajanian; Nadeem R Abu-Rustum; Marc Ladanyi
Journal:  Clin Cancer Res       Date:  2021-02-18       Impact factor: 12.531

9.  Mismatch repair deficiency and clinicopathological characteristics in endometrial carcinoma: a systematic review and meta-analysis.

Authors:  Alaa Salah Jumaah; Hawraa Sahib Al-Haddad; Mais Muhammed Salem; Katherine Ann McAllister; Akeel Abed Yasseen
Journal:  J Pathol Transl Med       Date:  2021-04-14

10.  Inactivating Mutations of the IK Gene Weaken Ku80/Ku70-Mediated DNA Repair and Sensitize Endometrial Cancer to Chemotherapy.

Authors:  Chao Gao; Guangxu Jin; Elizabeth Forbes; Lingegowda S Mangala; Yingmei Wang; Cristian Rodriguez-Aguayo; Paola Amero; Emine Bayraktar; Ye Yan; Gabriel Lopez-Berestein; Russell R Broaddus; Anil K Sood; Fengxia Xue; Wei Zhang
Journal:  Cancers (Basel)       Date:  2021-05-20       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.